Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMGN Amgen

Trading 01-27 12:14:04 EST

280.17

+4.75

+1.72%

High281.20	Low276.18	Vol1.30M
Open277.37	D1 Closing275.42	Amplitude1.82%
Mkt Cap150.60B	Tradable Cap150.21B	Total Shares537.53M
T/O361.28M	T/O Rate0.24%	Tradable Shares536.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"Amgen","latestPrice":280.165,"timestamp":1737998040199,"preClose":275.42,"halted":0,"volume":1296424,"delay":0,"floatShares":536156961,"shares":537532723,"eps":7.832929,"marketStatus":"Trading","change":4.745,"latestTime":"01-27 12:14:04 EST","open":277.37,"high":281.2,"low":276.18,"amount":361280660.02248,"amplitude":0.018227,"askPrice":280.19,"askSize":16,"bidPrice":280.03,"bidSize":168,"shortable":3,"etf":0,"ttmEps":7.832929,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1738011600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":275.42,"dividendRate":0.031696,"preHourTrading":{"tag":"盘前","latestPrice":277.9,"preClose":275.42,"latestTime":"09:29 EST","volume":219079,"amount":60358258.1189,"timestamp":1737988193551},"postHourTrading":{"tag":"盘后","latestPrice":274.2637,"preClose":275.42,"latestTime":"19:52 EST","volume":160412,"amount":44179332.0099,"timestamp":1737766339442},"volumeRatio":1.008275,"impliedVol":0.2772,"impliedVolPercentile":0.516},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"2506061813","title":"How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2506061813","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506061813?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:00","pubTimestamp":1737986413,"startTime":"0","endTime":"0","summary":"Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to look at a qualifying stock. Catalyst Pharmaceutical  holds a Zacks Rank #3 at the moment and its Most Accurate Estimate comes in at $0.54 a share 30 days away from its upcoming earnings release on February 26, 2025.To read this article on Zacks.com click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/boost-portfolio-top-medical-stocks-140013009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AMGN","CPRX"],"gpt_icon":0},{"id":"2506131668","title":"Janux Therapeutics Promotes Zachariah McIver to Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2506131668","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506131668?lang=en_us&edition=fundamental","pubTime":"2025-01-25 05:18","pubTimestamp":1737753492,"startTime":"0","endTime":"0","summary":"Janux Therapeutics (JANX) said Friday it promoted Zachariah McIver to chief medical officer.McIver was previously the executive medical director at Amgen (AMGN) for more than four years, the biopharmaceutical company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1057294990.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4581","LU2242652126.USD","LU0289739699.SGD","JANX","AMGN","LU0889565916.HKD","LU0122379950.USD","BK4534","LU0320765992.SGD","LU2242646821.SGD","LU1983299246.USD","BK4585","LU0109394709.USD","SG9999001440.SGD","BK4539","LU0058720904.USD","LU1571399168.USD","BK4139","BK4566","LENZ","BK4599","IE00B2B36J28.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU2112291526.USD","LU0868494617.USD","IE00B4R5TH58.HKD","BK4533","BK4588","IE0002141913.USD","IE00BJT1NW94.SGD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2506967998","title":"Amgen Price Target Maintained With a $324.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2506967998","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506967998?lang=en_us&edition=fundamental","pubTime":"2025-01-25 02:05","pubTimestamp":1737741900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 24, 2025 13:05 ET (18:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"gpt_icon":0},{"id":"2505334850","title":"Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2505334850","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505334850?lang=en_us&edition=fundamental","pubTime":"2025-01-24 21:07","pubTimestamp":1737724026,"startTime":"0","endTime":"0","summary":"Novo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"4b721982a3c5523099b212b13e715832","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novo-nordisk-stock-jumps-experimental-weight-loss-drug-trial-results/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU1061106388.HKD","LU1551013342.USD","IE00BK4W5M84.HKD","NVO.AU","LU2361044949.HKD","GB00BDT5M118.USD","NVO","LU2264538146.SGD","LU0256863811.USD","LLY","LU1868836757.USD","LU2242646821.SGD","LU2468319806.SGD","LU1983299246.USD","VKTX","IE00BZ1G4Q59.USD","IE0004445239.USD","IE0009355771.USD","LU0109391861.USD","LU2211815571.USD","IE00BKVL7J92.USD","LU1917777945.USD","LU0640476718.USD","LU1551013425.SGD","BK7104","LU0466842654.USD","LU0203201768.USD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU2361045086.USD","SGXZ51526630.SGD","LU0096364046.USD","LU0385154629.USD","LU1069344957.HKD","LU2237443978.SGD","LU2461242641.AUD","LU1712237335.SGD","LU1868837136.USD","SG9999018865.SGD","IE00BJJMRZ35.SGD","SG9999015952.SGD","LU2491050071.SGD","LU1093756325.SGD","LU1057294990.SGD","LU2237443549.SGD","LU0417517546.SGD","LU2491050154.USD","AMGN","LU2324357040.USD","LU1035775433.USD"],"gpt_icon":0},{"id":"2505856185","title":"Amgen (AMGN) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2505856185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505856185?lang=en_us&edition=fundamental","pubTime":"2025-01-24 19:57","pubTimestamp":1737719848,"startTime":"0","endTime":"0","summary":"In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $324.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/amgen-amgn-receives-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/amgen-amgn-receives-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1061106388.HKD","LU0122379950.USD","LU0868494617.USD","BK4581","LU0320765992.SGD","LU2242646821.SGD","IE00BFTCPJ56.SGD","BK4139","IE00B4R5TH58.HKD","LU0058720904.USD","BK4207","LU1983299246.USD","IE0009355771.USD","BK4534","LU2112291526.USD","IE00B2B36J28.USD","BK4588","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4566","LU0109394709.USD","BK4599","IE00BJJMRZ35.SGD","BK4585","LU1057294990.SGD","LU2242652126.USD","LU1571399168.USD","LU0889565916.HKD","IE0002141913.USD","BK4533","SG9999001440.SGD","AMGN"],"gpt_icon":0},{"id":"2505075994","title":"Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing","url":"https://stock-news.laohu8.com/highlight/detail?id=2505075994","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505075994?lang=en_us&edition=fundamental","pubTime":"2025-01-24 07:00","pubTimestamp":1737673219,"startTime":"0","endTime":"0","summary":"Amgen  ended the recent trading session at $277.88, demonstrating a +1.62% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.53%. Meanwhile, the Dow gained 0.93%, and the Nasdaq, a tech-heavy index, added 0.22%.Coming into today, shares of the world's largest biotech drugmaker had gained 3.38% in the past month. In that same time, the Medical sector gained 1.49%, while the S&P 500 gained 2.69%.Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-amgn-surpasses-market-returns-230019867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2112291526.USD","BK4534","BK4533","IE00BJT1NW94.SGD","LU2242646821.SGD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU1061106388.HKD","BK4139","LU1057294990.SGD","LU1023059063.AUD","IE0009355771.USD","BK4566","IE0002141913.USD","BK4588","LU0122379950.USD","BK4581","LU0109394709.USD","LU1571399168.USD","LU0889565916.HKD","BK4599","BK4585","IE00B4R5TH58.HKD","AMGN","LU2242652126.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU0868494617.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2505216390","title":"Amgen Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2505216390","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505216390?lang=en_us&edition=fundamental","pubTime":"2025-01-24 05:35","pubTimestamp":1737668100,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Amgen Inc.  advanced 1.62% to $277.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.53% to 6,118.71 and the Dow Jones Industrial Average  rising 0.92% to 44,565.07.Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson  rose 0.94% to $146.64 and Pfizer Inc.  rose 1.65% to $26.44.Trading volume  remained 1.8 million below its 50-day average volume of 4.0 M.Data source: Dow Jones Market Data, FactSet. Data compiled January 23, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"gpt_icon":0},{"id":"2505801400","title":"How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2505801400","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505801400?lang=en_us&edition=fundamental","pubTime":"2025-01-23 22:00","pubTimestamp":1737640809,"startTime":"0","endTime":"0","summary":"Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.The Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information. With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate  against the overall Zacks Consensus Estimate. The percentage differenc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/boost-portfolio-top-medical-stocks-140009880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AMGN","MRNA"],"gpt_icon":0},{"id":"2505016436","title":"SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2505016436","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505016436?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:48","pubTimestamp":1737636480,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the European Commission  has granted marketing authorization to expand the use of its multiple myeloma  drug, Sarclisa .With this nod, Sarclisa is now approved, in combination with Velcade  and Bristol Myers’ BMY Revlimid  and dexamethasone , for the treatment of patients with newly diagnosed MM  who are not eligible forautologous stem cell transplant.This approval was expected as the EMA’s Committee for Medicinal Products for Human Use  issued a positive opinion recommending the approval of the Sarclisa-VRd combo in the above indication in November.The EC and CHMP decisions are based on data from the phase III IMROZ study, which evaluated Sarclisa plus standard-of-care  VRd in NDMM patients who are not eligible for transplant. The study met its primary endpoint — treatment with the Sarclisa-VRd combination reduced the risk of disease progression or death by 40% compared to VRd in the given patient population.Following this approval, Sarclisa became the first ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snys-sarclisa-gets-eu-nod-124800696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868836757.USD","LU0985481810.HKD","LU1732799900.SGD","LU2133065610.SGD","LU0889566641.SGD","LU1267930813.SGD","BK4599","IE00BSNM7G36.USD","LU1059921491.USD","LU1066051225.USD","BK4550","LU1093756325.SGD","LU1244550221.USD","LU0456855351.SGD","LU0345769631.USD","IE00BFTCPJ56.SGD","LU1670711123.USD","IE00BDGV0183.EUR","BK4213","IE00B19Z3B42.SGD","LU2112291526.USD","SNY","BK4592","JNJ","AMGN","LU0868494617.USD","LU2242646821.SGD","LU1989771016.USD","LU1894683348.USD","BMY","SOC","LU0234572021.USD","IE00BVYPNW00.USD","IE0002141913.USD","LU1323610961.USD","LU1221951046.USD","LU1032955483.USD","LU1066051811.HKD","LU1221951129.SGD","LU0321505868.SGD","LU0234570918.USD","LU1061106388.HKD","LU1983299246.USD","LU0306806265.USD","LU1914381329.SGD","SG9999002232.USD","LU0225771236.USD","LU1585245621.USD","LU0320765646.SGD"],"gpt_icon":1},{"id":"2505705234","title":"Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2505705234","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505705234?lang=en_us&edition=fundamental","pubTime":"2025-01-23 04:43","pubTimestamp":1737578630,"startTime":"0","endTime":"0","summary":"Stifel initiated coverage on Cytokinetics Incorporated , noting the company’s catalyst rich one to two years.The M&A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 trial data ofaficamten in December 2023. However, last year,Novartis AG  decided to step back from pursuing theCytokinetics deal.Amgen Inc , AstraZeneca Plc , and Johnson & Johnson  also all popped up as potential suitors, though the stock faded from there as a deal never materialized.Also Read: Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study. Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc  deal and no mergers or acquisitions.Stifel has initiated coverage with a Buy rating and a price forecast of $80. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.Stifel analyst James Cond","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytokinetics-heart-drugs-future-sparks-204350038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","BK4578","RPRX","NQmain","SG9999002232.USD","BMY","TQQQ","LU2125154778.USD","LU0203347892.USD","LU1670711123.USD","LU1732800096.USD","BK4534","LU1066053197.SGD","NVS","LU0237698245.USD","LU1718418525.SGD","SG9999001440.SGD","USAW.SI","LU2242646821.SGD","LU1196500208.SGD","LU1074936037.SGD","LU1244550221.USD","LU1929549753.HKD","SQQQ","NVIW.SI","AZN",".IXIC","IE0002270589.USD","LU0203345920.USD","MNQmain","TSYW.SI","LU0345770308.USD","LU2242652126.USD","LU1267930813.SGD","LU2133065610.SGD","PSQ","QID","LU2417539215.USD","LU1066051811.HKD","QLD","CYTK","LU0320765992.SGD","LU0096364046.USD","BK4559","IE00BSNM7G36.USD","LU0345769631.USD","JNJ","BK4533","AMGN"],"gpt_icon":1},{"id":"2505272710","title":"GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2505272710","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505272710?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:53","pubTimestamp":1737553980,"startTime":"0","endTime":"0","summary":"The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions, kidney diseases and brain ailments.New evidence regarding the additional benefits  and risks of glucagon-like peptide-1  receptor agonists from a large study in nearly two million diabetes patients was published in Nature Medicine on Jan. 20, 2025.Data from the study, conducted over roughly 3.5 years, suggest that GLP-1 drugs compared to other diabetes medications were associated with a reduced risk of numerous conditions, including heart disease, stroke and kidney disease. They decreased the risk of psychotic disorders by 18%, Alzheimer’s disease by 12% and addiction disorders by an average of 13%.Novo Nordisk markets its blockbuster semaglutide  medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/glp-1-drugs-cut-risk-135300779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999018857.SGD","IE00BK4W5M84.HKD","LU1623119135.USD","SG9999017495.SGD","IE0002141913.USD","LU0094547139.USD","LU0203201768.USD","NVO","LU0471298777.SGD","LU2089984988.USD","BK4139","LU0320765992.SGD","LU1868836591.USD","LU2360106947.USD","VKTX","LU1069344957.HKD","LU0689472784.USD","LLY","LU0238689110.USD","LU1868836914.USD","LU2491050071.SGD","LU0114720955.EUR","LU1974910355.USD","LU2237443978.SGD","LU2357305700.SGD","LU0354030438.USD","LU2063271972.USD","LU2023250504.SGD","GLP","LU0672654240.SGD","LU1267930730.SGD","LU0154236417.USD","LU0079474960.USD","SG9999001176.SGD","LU0943347566.SGD","LU2237443465.HKD","LU0820561909.HKD","AMGN","LU1061106388.HKD","LU2211815571.USD","IE00B4R5TH58.HKD","LU0708995401.HKD","LU0198837287.USD","LU2112291526.USD","LU0203202063.USD","LU0471298694.HKD","LU0320765059.SGD","LU0097036916.USD","LU0256863902.USD","LU0256863811.USD"],"gpt_icon":1},{"id":"2505787493","title":"Arcus Taps Amgen Exec Richard Markus as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505787493","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505787493?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:43","pubTimestamp":1737495780,"startTime":"0","endTime":"0","summary":"Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer.The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled to begin the role on Jan. 31.Markus previously worked at biotechnology company Amgen for 13 years in various roles, including vice president of global development. Most recently, he founded an oncology-focused drug company called Dantari, where he served as chief executive.Markus succeeds Dimitry Nuyten, who is set to depart the company to pursue other opportunities. In 2023, Nuyten made a base salary of $562,000 and a total compensation of $3.69 billion, according to a filing from the company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0122379950.USD","LU0868494617.USD","BK4581","LU0320765992.SGD","LU2242646821.SGD","IE00BFTCPJ56.SGD","BK4139","IE00B4R5TH58.HKD","LU0058720904.USD","LU1983299246.USD","IE0009355771.USD","BK4534","LU2112291526.USD","IE00B2B36J28.USD","RCUS","BK4588","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4566","LU0109394709.USD","BK4599","IE00BJJMRZ35.SGD","BK4585","LU1057294990.SGD","LU2242652126.USD","LU1571399168.USD","LU0889565916.HKD","IE0002141913.USD","BK4533","SG9999001440.SGD","AMGN"],"gpt_icon":0},{"id":"2505002532","title":"Amgen 2025 guidance could miss estimates, says Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2505002532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505002532?lang=en_us&edition=fundamental","pubTime":"2025-01-22 02:45","pubTimestamp":1737485136,"startTime":"0","endTime":"0","summary":"Wells Fargo sees downside to Amgen’s (AMGN) 2025 consensus estimates, saying the company’ sales guidance could came in below expectations. It model...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-2025-guidance-could-miss-estimates-says-wells-fargo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-2025-guidance-could-miss-estimates-says-wells-fargo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","LU1035773651.USD","LU0289960550.SGD","LU0971096721.USD","LU0289739699.SGD","LU1069347547.HKD","LU1668664300.SGD","LU1814569148.SGD","IE00B2B36J28.USD","LU0477156953.USD","BK4534","LU0310800965.SGD","LU0251142724.SGD","LU1363072403.SGD","BK4501","LU0640476718.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU0648001328.SGD","LU1023059063.AUD","LU1201861249.SGD","AMGN","LU0128525689.USD","LU1057294990.SGD","LU2361044865.SGD","LU0320765489.SGD","LU1983299246.USD","LU1074936037.SGD","LU0072461881.USD","LU0417517546.SGD","LU2461242641.AUD","LU1791807156.HKD","LU0162691827.USD","LU2242652126.USD","BK4533","BK4588","LU0251131958.USD","IE0009355771.USD","LU0052756011.USD","IE00BFTCPJ56.SGD","BK4504","LU1061106388.HKD","LU2361045086.USD","SG9999001440.SGD","IE0002141913.USD","LU0175139822.USD","LU0208291251.USD","BK4581","LU1571399168.USD","BK4559"],"gpt_icon":0},{"id":"2505247120","title":"The race for the next Ozempic is on","url":"https://stock-news.laohu8.com/highlight/detail?id=2505247120","media":"Quartz","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505247120?lang=en_us&edition=fundamental","pubTime":"2025-01-21 18:00","pubTimestamp":1737453600,"startTime":"0","endTime":"0","summary":"Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. - Image: UCG / Contributor . Novo Nordisk’s  CagriSema and Amgen’s  MariTide both fell short of an expected 25% average weight-loss target in late-stage trials late last year, leaving investors frustrated and sending their stock prices tumbling.These medications, known commonly as GLP-1 or incretin drugs, have taken the world by storm — especially in the United States. Popularized by Ozempic, these treatments mimic gut hormones that regulate blood sugar and suppress appetite, making them highly sought after for their weight-loss effects. Popular brand names of these treatments currently on the market include Novo Nordisk’s Wegovy, which shares the same active ingredient with Ozempic, and Eli Lilly’s  Zepbound.The weight-loss drug boom has turned Novo Nordisk and Eli Lilly into the world’s most valuable pharmaceutical companies, with sales skyrocketing in recent years. Morgan Stanle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/race-next-ozempic-100000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999015986.USD","SG9999017495.SGD","LU0354030511.USD","LU1127390331.HKD","NVO","LU1363072403.SGD","LU2361044865.SGD","IE00BZ1G4Q59.USD","VKTX","LU2237443549.SGD","LU1712237335.SGD","LU2023250504.SGD","SGXZ31699556.SGD","IE00BJT1NW94.SGD","IE000M9KFDE8.USD","LU0114720955.EUR","LU0321505868.SGD","LU0256863902.USD","LU0094547139.USD","LU2265009873.SGD","LU1883839398.USD","LU0225284248.USD","LU2089984988.USD","LU0689472784.USD","PFE","IE00BLSP4452.SGD","LU1074936037.SGD","SG9999018857.SGD","LU0321505439.SGD","BK4566","LU2237443382.USD","BK4588","LU1548497426.USD","SG9999003800.SGD","LU1069344957.HKD","LU0820561909.HKD","BK4007","LU0238689110.USD","LU1868837300.USD","LU2491050154.USD","LU0061475181.USD","LLY","IE00BBT3K403.USD","AMGN","SG9999001440.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU0058720904.USD","LU2237443895.HKD"],"gpt_icon":1},{"id":"2505287123","title":"Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505287123","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505287123?lang=en_us&edition=fundamental","pubTime":"2025-01-20 22:18","pubTimestamp":1737382680,"startTime":"0","endTime":"0","summary":"Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras , in combination with its anti-EGFR antibody, Vectibix , for treating KRAS G12C-mutated metastatic colorectal cancer .The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult patients who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.Lumakras is presently approved for treating advanced or metastatic non-small cell lung cancer . The drug was approved in the United States in May 2021 and in the EU  in January 2022.In the past year, shares of Amgen have dropped 12.2% compared with the industry’s decline of 14.1%.Lumakras’ approval for the mCRC indication was based on data from the phase III CodeBreaK 300 study, which evaluated Lumakras plus Vectibix versus the investigator's choice of therapy in KRAS G12C–mutated mCRC.Data from the CodeBreaK 300 study also showed that treatment with Lumakras plus Vectibix demonstrated favorable ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgens-lumakras-gets-fda-nod-141800343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","LU2242646821.SGD","LU0122379950.USD","LU1061106388.HKD","LU2242652126.USD","LU1057294990.SGD","SOC","CSTL","BK4534","BK4599","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","AMGN","BK4196","IE00B2B36J28.USD","VYGR","LU0320765992.SGD","BK4581","LU0868494617.USD","LU1983299246.USD","BK4195","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU1571399168.USD","BK4213","LU0289739699.SGD","BK4139","SG9999001440.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","BK4211","BK4585","CTMX","LU0058720904.USD","LU0109394709.USD","IE0009355771.USD","BK4566","LU1023059063.AUD","LU2112291526.USD","PFS","BK4588"],"gpt_icon":0},{"id":"2504288601","title":"Amgen Inc. (AMGN): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2504288601","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504288601?lang=en_us&edition=fundamental","pubTime":"2025-01-20 20:47","pubTimestamp":1737377276,"startTime":"0","endTime":"0","summary":"We came across abullish thesison Amgen Inc.  on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc. 's share was trading at $272.11 as of Jan 17th. AMGN’s trailing and forward P/E were 34.75 and 13.07 respectively according to Yahoo Finance.In light of these dynamics, the current market sentiment presents a buying opportunity for AMGN. By focusing on the company’s long-term growth catalysts, including its oncology pipeline and strong product portfolio, rather than short-term fluctuations, investors can position themselves to benefit from the significant upsid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-inc-amgn-bull-case-124756266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1061106388.HKD","LU0122379950.USD","LU0868494617.USD","BK4581","LU0320765992.SGD","LU2242646821.SGD","IE00BFTCPJ56.SGD","BK4139","IE00B4R5TH58.HKD","LU0058720904.USD","LU1983299246.USD","IE0009355771.USD","BK4534","LU2112291526.USD","IE00B2B36J28.USD","BK4588","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4566","LU0109394709.USD","BK4599","IE00BJJMRZ35.SGD","BK4585","LU1057294990.SGD","LU2242652126.USD","LU1571399168.USD","LU0889565916.HKD","IE0002141913.USD","BK4533","SG9999001440.SGD","AMGN"],"gpt_icon":0},{"id":"2504415687","title":"Here’s Why Amgen Inc. (AMGN) Is Among the Highest Yielding Dividend Stocks In the Dow","url":"https://stock-news.laohu8.com/highlight/detail?id=2504415687","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504415687?lang=en_us&edition=fundamental","pubTime":"2025-01-20 07:19","pubTimestamp":1737328740,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow.In this article, we are going to take a look at where Amgen Inc.  stands against the other high yield dividend stocks.Dow is one of the most well-known and influential stock market indices globally. It monitors the performance of 30 publicly traded companies on US stock exchanges, covering a broad array of industries. In the past 12 months, the index has surged by over 15%, compared with a nearly 25% return of the broader market.When evaluating dividend yields, many investors adopt the 'Dogs of the Dow' strategy, which involves picking the ten Dow stocks with the highest dividend yields. While this strategy hasn't performed well in recent years, it has historically outpaced its benchmark over the long term. Michael","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-amgen-inc-amgn-among-231900457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","QLD","NVIW.SI","BK4533","IE00BJT1NW94.SGD","LU0122379950.USD","LU0289739699.SGD","NQmain","BK4585","LU2112291526.USD","BK4599","SQQQ","IE00BJJMRZ35.SGD","USJW.SI","PSQ","LU1983299246.USD","LU0320765992.SGD","LU0868494617.USD","MNQmain","LU1571399168.USD","LU1023059063.AUD","LU0109394709.USD","LU2242652126.USD","USAW.SI","BK4534","IE00B4R5TH58.HKD",".IXIC","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4588","QID","IE0009355771.USD","LU0058720904.USD","LU1057294990.SGD","LU1061106388.HKD","AMGN","LU2242646821.SGD","BK4139","TSYW.SI","BK4566","SG9999001440.SGD","TQQQ"],"gpt_icon":1},{"id":"2504380424","title":"Why Amgen Inc. (AMGN) Is One of the Best Cheap Stocks to Buy for 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504380424","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504380424?lang=en_us&edition=fundamental","pubTime":"2025-01-19 08:05","pubTimestamp":1737245131,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025.In this article, we are going to take a look at where Amgen Inc.  stands against other best cheap stocks to buy for 2025.The U.S. consumer prices report released this week revealed a less-than-expected increase in December, signaling a potential cooling in inflation pressures. This data has sparked bets on further tame inflation and a drop in interest rates. The core consumer price index , which excludes volatile food and energy prices, increased by 0.2%, down from 0.3% over the previous four months. This marks the first decrease in the rate of core CPI growth in six months, driven by lower hotel prices, slower increases in medical care costs, and moderate rent growth.When asked about the exact timing of potential rate cuts, Waller indicated that much depends on the continued improvement in inflation data. He stressed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-amgen-inc-amgn-one-000531395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["US6M.BOND","LU1061106388.HKD","USJW.SI","NQmain","US30Y.BOND","TQQQ","US3Y.BOND","LU0289739699.SGD","BK4534","BK4588","BK4139","SG9999001440.SGD","USAW.SI","LU2242646821.SGD","LU1983299246.USD","IE0002141913.USD","US10Y.BOND","BK4533","BK4585","LU0889565916.HKD","BK4566","IE00BFTCPJ56.SGD","LU1057294990.SGD","US12M.BOND","SQQQ","IE00BJT1NW94.SGD","IE00B2B36J28.USD","NVIW.SI","CPI","LU1571399168.USD",".IXIC","TSYW.SI","MNQmain","LU2242652126.USD","PSQ","QID","QLD","LU0868494617.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU1023059063.AUD","LU2112291526.USD","BK4599","US7Y.BOND","US2Y.BOND","IE00BJJMRZ35.SGD","AMGN","LU0109394709.USD","US5Y.BOND"],"gpt_icon":1},{"id":"2504010332","title":"Ozempic, Xtandi among next 15 drugs selected for U.S. price talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2504010332","media":"TipRanks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504010332?lang=en_us&edition=fundamental","pubTime":"2025-01-18 21:20","pubTimestamp":1737206448,"startTime":"0","endTime":"0","summary":"The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027, the agency said in a statement. The selected drug list for the second cycle of negotiations is: Novo Nordisk’s  Ozempic, Rybelsus, and Wegovy, GSK‘s  Trelegy Ellipta, Pfizer’s  Xtandi, Bristol Myers’  Pomalyst, Pfizer’s  Ibrance, Boehringer Ingleheim’s Ofev, AbbVie  and Ironwood’s  Linzess, AstraZeneca’s  Calquence, Teva‘s  Austedo, GSK and Theravance’s  Breo Ellipta, Boehringer’s Tradjenta, Salix’s  Xifaxan, AbbVie’s Vraylar, Merck’s  Janumet, and Amgen’s  Otezla. Companies with a selected drug will have until February 28 to decide if they will participate in negotiations.Discover outperforming sto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ozempic-xtandi-among-next-15-132048211.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ozempic-xtandi-among-next-15-132048211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002232.USD","IE00B3PB1722.GBP","SG9999015952.SGD","LU0320765489.SGD","LU0256863902.USD","LU0109394709.USD","LU1003077747.HKD","BMY","IE00B19Z3B42.SGD","LU0029864427.USD","SGXZ57979304.SGD","SG9999001440.SGD","TEVA","LU1323610961.USD","LU2023250843.SGD","LU2361045086.USD","LU0306807586.USD","IRWD","NVO","SG9999003800.SGD","IE00BVYPNV92.GBP","IE00B42XCP33.USD","LU0234570918.USD","AZN","IE00B2B36J28.USD","LU2468319806.SGD","LU2461242641.AUD","BK4581","LU2236285917.USD","LU1699723380.USD","LU2023250504.SGD","LU2417539215.USD","LU2237443622.USD","LU1989771016.USD","AMGN","LU0417517546.SGD","LU1037948541.HKD","ABBV","LU0256863811.USD","IE00BDGV0183.EUR","SG9999014575.USD","LU2462157665.USD","BHC","GSK","MRK","GSK.UK","PFE","TBPH","LU1571399168.USD","LU1941712348.USD"],"gpt_icon":1},{"id":"2504223141","title":"Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing","url":"https://stock-news.laohu8.com/highlight/detail?id=2504223141","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504223141?lang=en_us&edition=fundamental","pubTime":"2025-01-18 06:50","pubTimestamp":1737154218,"startTime":"0","endTime":"0","summary":"Amgen  closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, the Dow experienced a rise of 0.78%, and the technology-dominated Nasdaq saw an increase of 1.51%.Heading into today, shares of the world's largest biotech drugmaker had gained 3.15% over the past month, outpacing the Medical sector's loss of 1.36% and the S&P 500's loss of 2.14% in that time.The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on February 4, 2025. The company is predicted to post an EPS of $5.02, indicating a 6.58% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.85 billion, up 7.92% from the year-ago period.Today, you can download 7 Best Stocks for the Next 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-amgn-rises-yet-lags-225018679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4581","LU1023059063.AUD","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4533","BK4534","LU0289739699.SGD","BK4585","IE0009355771.USD","LU0320765992.SGD","LU1061106388.HKD","LU0889565916.HKD","BK4139","LU1983299246.USD","LU2242652126.USD","IE00B4R5TH58.HKD","BK4588","LU2242646821.SGD","IE00BJT1NW94.SGD","SG9999001440.SGD","BK4599","IE00BFTCPJ56.SGD","IE0002141913.USD","AMGN","LU0109394709.USD","LU0058720904.USD","LU1571399168.USD","LU0868494617.USD","IE00B2B36J28.USD","LU2112291526.USD","LU0122379950.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0413},{"period":"3month","weight":-0.1311},{"period":"6month","weight":-0.1775},{"period":"1year","weight":-0.1123},{"period":"ytd","weight":0.0567}],"compareEarnings":[{"period":"1week","weight":0.0174},{"period":"1month","weight":0.0111},{"period":"3month","weight":0.05},{"period":"6month","weight":0.1167},{"period":"1year","weight":0.2458},{"period":"ytd","weight":0.0373}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.03318},{"month":2,"riseRate":0.463415,"avgChangeRate":-0.003118},{"month":3,"riseRate":0.512195,"avgChangeRate":0.019417},{"month":4,"riseRate":0.463415,"avgChangeRate":-0.001307},{"month":5,"riseRate":0.536585,"avgChangeRate":0.024998},{"month":6,"riseRate":0.512195,"avgChangeRate":0.004729},{"month":7,"riseRate":0.761905,"avgChangeRate":0.052458},{"month":8,"riseRate":0.619048,"avgChangeRate":0.005154},{"month":9,"riseRate":0.52381,"avgChangeRate":0.002807},{"month":10,"riseRate":0.52381,"avgChangeRate":0.020682},{"month":11,"riseRate":0.619048,"avgChangeRate":0.019128},{"month":12,"riseRate":0.642857,"avgChangeRate":0.047779}],"exchange":"NASDAQ","name":"Amgen","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amgen(AMGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amgen,AMGN,Amgen股票,Amgen股票老虎,Amgen股票老虎国际,Amgen行情,Amgen股票行情,Amgen股价,Amgen股市,Amgen股票价格,Amgen股票交易,Amgen股票购买,Amgen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amgen(AMGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction